Skip to main content

Articles

Page 2 of 13

  1. Impaired neutrophil activity is an important issue in chronic lymphocytic leukemia (CLL), as it contributes to a dysfunctional immune response leading to life-threatening infections in patients. Some features ...

    Authors: Agnieszka Goral, Marta Sledz, Aneta Manda-Handzlik, Adrianna Cieloch, Alicja Wojciechowska, Mieszko Lachota, Agnieszka Mroczek, Urszula Demkow, Radoslaw Zagozdzon, Katarzyna Matusik, Malgorzata Wachowska and Angelika Muchowicz
    Citation: Experimental Hematology & Oncology 2023 12:89
  2. CAR T cell therapy has been successfully used in the treatment of hematological malignancies, and the strategy that deletion of inhibitory receptor on the CAR T cell surface, such as PD-1, greatly enhance the ...

    Authors: Ming Liu, Linlin Zhang, Mingtian Zhong, Yihao Long, Wenhui Yang, Ting Liu, Xingxu Huang and Xiaodong Ma
    Citation: Experimental Hematology & Oncology 2023 12:88
  3. Nucleophosmin (NPM1) is a widely expressed nucleocytoplasmic shuttling protein with prominent nucleolar localization. It is estimated that 25–35% of adult patients with acute myeloid leukemia (AML) carry NPM1 mut...

    Authors: Yiyi Yao, Xiangjie Lin, Chen Wang, Ying Gu, Jie Jin, Yinghui Zhu and Huafeng Wang
    Citation: Experimental Hematology & Oncology 2023 12:87
  4. Immunosuppression induced by programmed cell death protein 1 (PD1) presents a significant constraint on the effectiveness of chimeric antigen receptor (CAR)-T therapy. The potential of combining PD1/PDL1 (Prog...

    Authors: Ang Zhang, Shenyu Wang, Yao Sun, Yikun Zhang, Long Zhao, Yang Yang, Yijian Zhang, Lei Xu, Yangyang Lei, Jie Du, Hu Chen, Lian Duan, Mingyi He, Lintao Shi, Lei Liu, Quanjun Wang…
    Citation: Experimental Hematology & Oncology 2023 12:85
  5. Focal adhesion kinase (FAK), a nonreceptor cytoplasmic tyrosine kinase, is a vital participant in primary cellular functions, such as proliferation, survival, migration, and invasion. In addition, FAK regulate...

    Authors: Ximin Tan, Yuheng Yan, Bin Song, Shuangli Zhu, Qi Mei and Kongming Wu
    Citation: Experimental Hematology & Oncology 2023 12:83
  6. The pattern recognition receptor long pentraxin-3 (PTX3) plays conflicting roles in cancer by acting as an oncosuppressor or as a pro-tumor mediator depending on tumor context. Triple negative breast cancer (T...

    Authors: Arianna Giacomini, Marta Turati, Elisabetta Grillo, Sara Rezzola, Gaia Cristina Ghedini, Ander Churruca Schuind, Eleonora Foglio, Federica Maccarinelli, Jessica Faletti, Serena Filiberti, Angela Chambery, Mariangela Valletta, Laura Melocchi, Stephanie Gofflot, Barbara Chiavarina, Andrei Turtoi…
    Citation: Experimental Hematology & Oncology 2023 12:82
  7. In KMT2A-rearranged acute lymphoblastic leukemia (ALL), an aggressive malignancy, oncogenic KMT2A-fusion proteins inappropriately recruit DOT1L to promote leukemogenesis, highlighting DOT1L as an attractive thera...

    Authors: Pauline Schneider, Nicholas T. Crump, Susan T.C.J.M. Arentsen-Peters, Alastair L. Smith, Rico Hagelaar, Fabienne R.S. Adriaanse, Romy S. Bos, Anja de Jong, Stefan Nierkens, Bianca Koopmans, Thomas A. Milne, Rob Pieters and Ronald W. Stam
    Citation: Experimental Hematology & Oncology 2023 12:81
  8. Prostate cancer (PC) is one of the most common cancers in males and the fifth leading reason of death. Age, ethnicity, family history, and genetic defects are major factors that determine the aggressiveness an...

    Authors: Ganji Lakshmi Varaprasad, Vivek Kumar Gupta, Kiran Prasad, Eunsu Kim, Mandava Bhuvan Tej, Pratik Mohanty, Henu Kumar Verma, Ganji Seeta Rama Raju, LVKS Bhaskar and Yun Suk Huh
    Citation: Experimental Hematology & Oncology 2023 12:80
  9. Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin lymphoma subtype which remains incurable despite multimodal approach including chemoimmunotherapy followed by stem cell transplant, targeted approaches s...

    Authors: Wing Keung Chan, Jessica Williams, Kinnari Sorathia, Betsy Pray, Kaled Abusaleh, Zehua Bian, Archisha Sharma, Ian Hout, Shamama Nishat, Walter Hanel, Shelby L. Sloan, Aneeq Yasin, Nathan Denlinger, Xiaoli Zhang, Natarajan Muthusamy, Sumithira Vasu…
    Citation: Experimental Hematology & Oncology 2023 12:79
  10. Leiomyosarcoma (LMS) is a rare soft tissue sarcoma (STS) that begins in smooth muscle tissue and most often initiates in the abdomen or uterus. Compared with other uterine cancers, uterine LMS (ULMS) is an agg...

    Authors: Sonam Mittal, Ishaque Pulikkal Kadamberi, Hua Chang, Feng Wang, Sudhir Kumar, Shirng-Wern Tsaih, Christopher J. Walker, Pradeep Chaluvally-Raghavan, John Charlson, Yosef Landesman and Sunila Pradeep
    Citation: Experimental Hematology & Oncology 2023 12:78
  11. UTX (encoded by KDM6A), a histone demethylase for H3K27me2/3, is frequently mutated in human cancers. However, its functional and regulatory mechanisms in colorectal cancer (CRC) remain unclear.

    Authors: Dakui Luo, Min Chen, Qingguo Li, Kangjunjie Wang, Kaihua Wang, Junqiang Li, Guoxiang Fu, Zezhi Shan, Qi Liu, Yufei Yang, Lei Liang, Yanlei Ma, Yi Qin, Jun Qin, Daming Gao and Xinxiang Li
    Citation: Experimental Hematology & Oncology 2023 12:77
  12. T-cell acute lymphoblastic leukemia (T-ALL) is a hematologic tumor, characterized by several genetic alterations, that constitutes 15% of pediatric and 25% of adult ALL. While with current therapeutic protocol...

    Authors: Sonia Minuzzo, Valentina Agnusdei, Marica Pinazza, Adriana A. Amaro, Valeria Sacchetto, Ulrich Pfeffer, Roberta Bertorelle, Orietta Spinelli, Valentina Serafin and Stefano Indraccolo
    Citation: Experimental Hematology & Oncology 2023 12:76
  13. The mechanisms underlying the occurrence and development of esophageal squamous cell carcinoma (ESCC) remains to be elucidated. The present study aims to investigate the roles and implications of IGF2BP1 overe...

    Authors: Juan-Juan Wang, Ding-Xiong Chen, Yu Zhang, Xin Xu, Yan Cai, Wen-Qiang Wei, Jia-Jie Hao and Ming-Rong Wang
    Citation: Experimental Hematology & Oncology 2023 12:75
  14. Bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells have been employed in relapsed/refractory multiple myeloma (RRMM) patients over the past few years, as an increasing nu...

    Authors: Jiangxue Hou, Yufu Li and Quande Lin
    Citation: Experimental Hematology & Oncology 2023 12:74

    The Correction to this article has been published in Experimental Hematology & Oncology 2023 12:86

  15. Chimeric antigen receptor (CAR)-T cell therapy is one of the most promising advances in cancer treatment. It is based on genetically modified T cells to express a CAR, which enables the recognition of the spec...

    Authors: Cristina Aparicio, Carlos Acebal and Margarita González-Vallinas
    Citation: Experimental Hematology & Oncology 2023 12:73
  16. Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line immunochemotherapy, whereas nearly 30–40% of patients experience refractory or relapse. For several decades, the standard treatment s...

    Authors: Tingxun Lu, Jie Zhang, Zijun Y. Xu-Monette and Ken H. Young
    Citation: Experimental Hematology & Oncology 2023 12:72
  17. Multiple myeloma (MM) is an incurable plasma cell malignancy, accounting for approximately 1% of all cancers. Despite recent advances in the treatment of MM, due to the introduction of proteasome inhibitors (P...

    Authors: Cecilia Bandini, Elisabetta Mereu, Tina Paradzik, Maria Labrador, Monica Maccagno, Michela Cumerlato, Federico Oreglia, Lorenzo Prever, Veronica Manicardi, Elisa Taiana, Domenica Ronchetti, Mattia D’Agostino, Francesca Gay, Alessandra Larocca, Lenka Besse, Giorgio Roberto Merlo…
    Citation: Experimental Hematology & Oncology 2023 12:71
  18. Organoids are established through in vitro 3D culture, and they can mimic the structure and physiological functions of organs or tissues in vivo. Organoids have attracted much attention in recent years. They c...

    Authors: Zhen Fang, Peijuan Li, Fengying Du, Liang Shang and Leping Li
    Citation: Experimental Hematology & Oncology 2023 12:69
  19. Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Onco...

    Authors: Yuanhong Jiang, Siyu Wu, Rong Li, Jiazheng Yu, Jianyi Zheng, Zeyu Li, Mingyang Li, Kerong Xin, Zhenqun Xu, Shijie Li and Xiaonan Chen
    Citation: Experimental Hematology & Oncology 2023 12:68
  20. Increasing evidence suggests that immunotherapy, especially immune checkpoint inhibitors (ICIs), has the potential to facilitate long-term survival in various cancer besides prostate cancer. Emerging evidence ...

    Authors: Fei Wu, Minglei Wang, Tao Zhong, Changyan Xiao, Xiaozheng Chen, Yiheng Huang, Meng Wu, Jinming Yu and Dawei Chen
    Citation: Experimental Hematology & Oncology 2023 12:67
  21. The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing spora...

    Authors: Tingting Zhang, Weiwei Tian, Shuang Wei, Xinyi Lu, Jing An, Shaolong He, Jie Zhao, Zhilin Gao, Li Li, Ke Lian, Qiang Zhou, Huilai Zhang, Liang Wang, Liping Su, Huicong Kang, Ting Niu…
    Citation: Experimental Hematology & Oncology 2023 12:66
  22. Ferroptosis is a regulated cell death mode triggered by iron-dependent toxic membrane lipid peroxidation. As a novel cell death modality that is morphologically and mechanistically different from other forms o...

    Authors: Xiaogang Zheng, Xiaodong Jin, Fei Ye, Xiongxiong Liu, Boyi Yu, Zheng Li, Ting Zhao, Weiqiang Chen, Xinguo Liu, Cuixia Di and Qiang Li
    Citation: Experimental Hematology & Oncology 2023 12:65
  23. T cell-redirecting bispecific antibodies establish a connection between endogenous T cells and tumor cells, activating T cells function to eliminate tumor cells without ex vivo genetic alteration or manipulati...

    Authors: Manling Chen, Xiaoyu Liu, Nan Peng, Ting Zhang, Junli Mou, Huizhen He, Ying Wang, Yingxi Xu, Haiyan Xing, Kejing Tang, Zheng Tian, Qing Rao, Runxia Gu, Shaowei Qiu, Min Wang and Jianxiang Wang
    Citation: Experimental Hematology & Oncology 2023 12:64
  24. Triplet DCF (docetaxel, cisplatin and 5-flurouracil) and doublet CP/CF (carboplatin and paclitaxel/cisplatin and 5-fluorouracil) regimens were prospectively evaluated in advanced squamous anal cell carcinoma (...

    Authors: Stefano Kim, Véronique Vendrely, Angélique Saint, Thierry André, Pauline Vaflard, Emmanuelle Samalin, Simon Pernot, Oliver Bouché, Mustapha Zubir, Jérôme Desrame, Christelle de la Fouchardière, Denis Smith, François Ghiringhelli, Angélique Vienot, Marion Jacquin, Elodie Klajer…
    Citation: Experimental Hematology & Oncology 2023 12:63
  25. Fibronectin, an extracellular matrix protein, has been reported to be associated with heterogeneous cancer stemness, angiogenesis and progression in multiple cancer types. However, the roles and the underlying...

    Authors: Fei Zhou, Jianguo Sun, Lingyun Ye, Tao Jiang, Wei Li, Chunxia Su, Shengxiang Ren, Fengying Wu, Caicun Zhou and Guanghui Gao
    Citation: Experimental Hematology & Oncology 2023 12:61
  26. Dysregulation of the innate immune system and inflammatory-related pathways has been implicated in hematopoietic defects in the bone marrow microenvironment and associated with aging, clonal hematopoiesis, mye...

    Authors: Charan Thej Reddy Vegivinti, Praneeth Reddy Keesari, Sindhusha Veeraballi, Catarina Maria Pina Martins Maia, Ansh Krishnachandra Mehta, Rohit Reddy Lavu, Rahul Kumar Thakur, Sri Harsha Tella, Riya Patel, Venkata Kiranmayi Kakumani, Yashwitha Sai Pulakurthi, Srinivas Aluri, Ritesh Kumar Aggarwal, Nandini Ramachandra, Rongbao Zhao, Srabani Sahu…
    Citation: Experimental Hematology & Oncology 2023 12:60
  27. Tumor initiation, progression, and response to therapies depend to a great extent on interactions between malignant cells and the tumor microenvironment (TME), which denotes the cancerous/non-cancerous cells, ...

    Authors: Yunru Gu, Yuan Fang, Xi Wu, Tingting Xu, Tong Hu, Yangyue Xu, Pei Ma, Qiang Wang and Yongqian Shu
    Citation: Experimental Hematology & Oncology 2023 12:58
  28. Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), w...

    Authors: Xubo Gong, Yi Zhang, Xin He, Milad Moloudizargari, Teng Yu, Lin Wang, Weiwei Liu, Lan Jin, Huiying Xu, Yang Xu, Zhihua Tao and Wenbin Qian
    Citation: Experimental Hematology & Oncology 2023 12:57
  29. Without the clear immunophenotyping of brain metastases (BrMs), the optimal treatment strategy based on PD-1/PD-L1 inhibitor for patients with non-small-cell lung cancer (NSCLC) and BrMs remains unknown.

    Authors: Haowei Wang, Fangfang Liu, Xiaoxia Chen, Chao Zhao, Xuefei Li, Caicun Zhou, Jie Hu, Qian Chu and Tao Jiang
    Citation: Experimental Hematology & Oncology 2023 12:56
  30. Ropeginterferon alfa-2b represents a new-generation pegylated interferon-based therapy and is administered every 2–4 weeks. It is approved for polycythemia vera (PV) treatment in the United States and Europe w...

    Authors: Jie Jin, Lei Zhang, Albert Qin, Daoxiang Wu, Zonghong Shao, Jie Bai, Suning Chen, Minghui Duan, Hu Zhou, Na Xu, Sujiang Zhang, Xuelan Zuo, Xin Du, Li Wang, Pei Li, Xuhan Zhang…
    Citation: Experimental Hematology & Oncology 2023 12:55
  31. Brain metastasis (BM) is an important cause of mortality for cancer patients. Many patients were diagnosed with brain metastases at their first visit who have not received any treatment while a subset of patie...

    Authors: Jianing Chen, Hainan Yang, Chao Zhao, Tao Lin, Da Liu, Weiping Hong, Changguo Shan, Cheng Zhou, Ling Bao, Caicun Zhou, Linbo Cai, Chunxia Su, Zhaoming Zhou and Lei Wen
    Citation: Experimental Hematology & Oncology 2023 12:54
  32. Non-small cell lung cancer (NSCLC) with HER2 mutation has entered into the era of targeted therapy. However, both anti-HER2 antibody–drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) showed moderate ob...

    Authors: Shiqi Mao, Shuo Yang, Xinyu Liu, Xingya Li, Qiming Wang, Yiping Zhang, Jianhua Chen, Yan Wang, Guanghui Gao, Fengying Wu, Tao Jiang, Jiao Zhang, Ying Yang, Xiang Lin, Xiaoyu Zhu, Caicun Zhou…
    Citation: Experimental Hematology & Oncology 2023 12:53
  33. Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death. The accumulation of genetic and epigenetic changes is closely related to the occurrence and development of HCC. Enhancer of zeste ho...

    Authors: Bohan Wang, Yachong Liu, Zhibin Liao, Haofeng Wu, Bixiang Zhang and Lei Zhang
    Citation: Experimental Hematology & Oncology 2023 12:52
  34. Soft-tissue sarcoma (STS) are a heterogeneous group of rare tumors with different biological behavior that are fatal in more than 40% of cases, due to their metastatic evolution and inadequate treatment option...

    Authors: M Spalato-Ceruso, A Laroche-Clary, R Perret, Y Valverde, V Chaire, Marie-Alix Derieppe, V Velasco, A Bourdon and A Italiano
    Citation: Experimental Hematology & Oncology 2023 12:51
  35. Thrombocytopenia occurs in 60% of patients with myelodysplastic syndromes (MDS), increasing the risk of life-threatening haemorrhage in this population of mainly old patients with comorbidities. However, data ...

    Authors: Pauline Durand, Valérie Pottier, Charles Mesguich, Frédéric Debordeaux, Estibaliz Lazaro, Jean-François Viallard and Etienne Rivière
    Citation: Experimental Hematology & Oncology 2023 12:50
  36. Metastasis is a crucial aspect of disease progression leading to death in patients with prostate cancer (PCa). However, its mechanism remains unclear. We aimed to explore the mechanism of lymph node metastasis...

    Authors: Shiyong Xin, Xiang Liu, Ziyao Li, Xianchao Sun, Rong Wang, Zhenhua Zhang, Xinwei Feng, Liang Jin, Weiyi Li, Chaozhi Tang, Wangli Mei, Qiong Cao, Haojie Wang, Jianguo Zhang, Lijin Feng and Lin Ye
    Citation: Experimental Hematology & Oncology 2023 12:49
  37. Approximately 60–80% of cancer patients treated with abdominopelvic radiotherapy suffer post-radiotherapy toxicities including radiation enteropathy and myelosuppression. Effective preventive and therapeutic s...

    Authors: Yuxi Yi, Weiqing Lu, Lijun Shen, Yang Wu and Zhen Zhang
    Citation: Experimental Hematology & Oncology 2023 12:48
  38. Drug resistance and poor treatment response are major obstacles to the effective treatment of acute myeloid leukemia (AML). A deeper understanding of the mechanisms regulating drug resistance and response gene...

    Authors: Xin Liu, Shuxin Zhong, Kangjie Qiu, Xi Chen, Weiyue Wu, Jiamian Zheng, Yanwen Liu, Haolong Wu, Shiyun Fan, Dingrui Nie, Xianfeng Wang, Zhi Yu, Ziwei Liao, Mengjun Zhong, Yangqiu Li and Chengwu Zeng
    Citation: Experimental Hematology & Oncology 2023 12:47
  39. Clear-cell renal cell carcinomas (ccRCCs) are malignant tumors with high metastatic potential and resistance to treatments occurs almost constantly. Compared to primary tumors, there are still limited genomic ...

    Authors: Thi Oanh Bui, Eurydice Angeli, Morad El Bouchtaoui, Guillaume Gapihan, Van Tu Dao, Justine Paris, Christophe Leboeuf, Michael Soussan, Patrick Villarese, Marianne Ziol, Emmanuel Van Glabeke, Thi Huong Le, Jean-Paul Feugeas, Anne Janin and Guilhem Bousquet
    Citation: Experimental Hematology & Oncology 2023 12:46
  40. Venetoclax (Ven) combined with intensive chemotherapy was proven effective in the management of acute myeloid leukemia (AML). However, the severe and prolonged myelosuppression remains a concern to worry about...

    Authors: Xiaohui Suo, Fang Zheng, Dongmei Wang, Liyun Zhao, Jie Liu, Ling Li, Zhihua Zhang, Congcong Zhang, Yinling Li, Sisi Yang, Xuemei Zhao, Rui Shi, Yan Wu, Zongjiu Jiao, Jiaojie Song, Ling Zhang…
    Citation: Experimental Hematology & Oncology 2023 12:45
  41. BCMA CAR-T is highly effective for relapsed/refractory multiple myeloma(R/R-MM) and significantly improves the survival of patients. However, the short remission time and high relapse rate of MM patients treat...

    Authors: Wei Li, Binglei Zhang, Weijie Cao, Wenli Zhang, Tiandong Li, Lina Liu, LinPing Xu, Fengcai Gao, Yanmei Wang, Fang Wang, Haizhou Xing, Zhongxing Jiang, Jianxiang Shi, Zhilei Bian and Yongping Song
    Citation: Experimental Hematology & Oncology 2023 12:44
  42. Head and neck squamous cell carcinoma (HNSCC) is highly aggressive with a significant tropism of lymph nodes, which restricts treatment options and negatively impacts patient outcomes. Although progress has be...

    Authors: Min Wang, Min Pan, Yanshi Li, Tao Lu, Zhihai Wang, Chuan Liu and Guohua Hu
    Citation: Experimental Hematology & Oncology 2023 12:43
  43. Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 conse...

    Authors: Olisaemeka D. Ogbue, Tariq Kewan, Waled S. Bahaj, Carmelo Gurnari, Valeria Visconte and Jaroslaw P. Maciejewski
    Citation: Experimental Hematology & Oncology 2023 12:42
  44. Recent evidence suggests that bispecific antibodies (BsAbs) exhibit promising efficacy and low toxicity even in heavily treated non-Hodgkin B-cell lymphoma (B-NHL). However, the role of BsAbs in previously unt...

    Authors: Zhijuan Lin, Long Liu, Zhifeng Li and Bing Xu
    Citation: Experimental Hematology & Oncology 2023 12:41
  45. We aim to examine the prognostic value of major pathologic response in metastatic lymph nodes (mLN-MPR) after immunochemotherapy in non-small cell lung cancer (NSCLC), and demonstrate the pathological characte...

    Authors: Hongsheng Deng, Shan Xiong, Ran Zhong, Yongmei Zheng, Hengrui Liang, Bo Cheng, Jianfu Li, Feng Li, Zhuxing Chen, Haixuan Wang, Jianxing He and Wenhua Liang
    Citation: Experimental Hematology & Oncology 2023 12:40

Annual Journal Metrics

  • 2022 Citation Impact
    11.4 - 2-year Impact Factor
    7.3 - 5-year Impact Factor
    1.609 - SNIP (Source Normalized Impact per Paper)
    1.908 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    100 days submission to accept (Median)

    2023 Usage
    696,150 downloads
    375 Altmetric mentions